<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070208</url>
  </required_header>
  <id_info>
    <org_study_id>RETRO-CBF</org_study_id>
    <nct_id>NCT05070208</nct_id>
  </id_info>
  <brief_title>Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor</brief_title>
  <acronym>RETRO-CBF</acronym>
  <official_title>Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acute Leukemia French Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acute Leukemia French Association</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Core Binding Factor leukemias represent a specific category of acute myeloid leukemias&#xD;
      that share prognostic factors, a specific mutational profile, and a favorable response to&#xD;
      chemotherapy. Their management now follows the reference pattern from the French trial&#xD;
      CBF-2006 closed to inclusions since November 2010. This includes intensive chemotherapy and&#xD;
      intensification by allogeneic marrow transplant depending on the residual disease measured by&#xD;
      RT qPCR . These leukemias have not been the subject of multicenter clinical trials since that&#xD;
      date.&#xD;
&#xD;
      The results of this treatment regimen need to be evaluated. Known prognostic factors such as&#xD;
      signaling mutations, clonal interference or residual disease follow-up (MRD) will be analyzed&#xD;
      and updated in this recent cohort. The interaction between residual disease and mutational&#xD;
      profile will be evaluated on the prognosis. Treatment with gemtuzumab-ozogamycin and&#xD;
      first-line allogeneic transplantation will be investigated, depending on prognostic factors&#xD;
      including associated mutations and residual disease. The course and early treatment of&#xD;
      molecular relapses will be analyzed. The treatment and prognosis of cytological relapses will&#xD;
      be described with in particular the role of tyrosine kinase inhibitors and therapeutic&#xD;
      intensification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NOT PROVIDED&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>December 2010 to December 2020</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Complete remission rate (CR / CRp)</measure>
    <time_frame>December 2010 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Overall survival (OS), relapse free survival (DFS) +/- censored with allogeneic transplant</measure>
    <time_frame>December 2010 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Cumulative incidence of relapse (CIR) +/- censored at allograft</measure>
    <time_frame>December 2010 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Second complete remission rate, OS, EFS, DFS and CIR post-relapse</measure>
    <time_frame>December 2010 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Prognostic impact on OS, CR, EFS, DFS and CIR of recurrent somatic mutations</measure>
    <time_frame>December 2010 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Interaction between mutations and MRD on OS, CR, EFS, DFS and CIR</measure>
    <time_frame>December 2010 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Cumulative incidence of molecular relapse.</measure>
    <time_frame>December 2010 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Prognostic impact on OS, CR, EFS, DFS, CIR and post-relapse survival of using first-line GO and relapsing</measure>
    <time_frame>December 2010 to December 2020</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Myeloblastic Leukemia Core Binding Factor</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NOT PROVIDED</intervention_name>
    <description>NOT PROVIDED</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Core Binding Factor Acute Myeloid Leukemia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years old&#xD;
&#xD;
          -  Diagnosis of acute myeloid leukemia with CBF confirmed by cytogenetics (karyotype and&#xD;
             / or FISH): t (8; 21), inv (16) or t (16; 16) and / or molecular biology&#xD;
             (RUNX1-RUNX1T1 fusions or CBFB-MYH11)&#xD;
&#xD;
          -  Initial management by intensive chemotherapy, hypomethylants or targeted therapies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Opposition expressed to research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>ITZYKSON Raphael, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>SAINT LOUIS PARIS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raphael ITZYKSON, Dr</last_name>
    <phone>+33 1 71 20 70 31</phone>
    <email>raphael.itzykson@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas BOISSEL, Pr</last_name>
    <phone>+33 1 42 49 96 09</phone>
    <email>nicolas.boissel@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEBON, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AL JIJAKLI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP-GHU - Hôpital AVICENNE</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BRAUN, MD-Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de la cote de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHANTEPIE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Métropole Savoie</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Matteo PICA</last_name>
    </contact>
    <investigator>
      <last_name>Gian Matteo PICA, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital MILITAIRE PERCY</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MALFUSON, MD-Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HAIAT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henri Mondor Aphp</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu LECLERC, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Mathieu LECLERC, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dijon Chu</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Lorrraine CHRETIEN, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Marie Lorrraine CHRETIEN, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WATTEBLED, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAMBERT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LENS CHR</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire BORIES, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Claire BORIES, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quesnel Bruno, Professor</last_name>
      <phone>33 3 20 44 42 90</phone>
      <email>bquesnel@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>QUESNEL BRUNO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limoges Chu</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien VAIDIE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Julien VAIDIE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FARNAULT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GASTAUD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nice,Hopital Archet 1</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CLUZEAU, MD-Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Pitié-Salpétrière APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UZUNOV, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARCAIS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis- APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ITZYKSON, MD-Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis GENTHON, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Alexis GENTHON, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HEIBLIG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VAIDA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Roubaix</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PLANTIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de St Quentin</name>
      <address>
        <city>Saint-Quentin</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GARIDI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MICOL, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

